Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A.L. Liamas
Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 MCG for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm89 - Database Analysis of a PSP (Patient Support Program) for Patients Using Interferon Beta-1a for Relapsing Multiple Sclerosis in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
Farmeconomia. Health economics and therapeutic pathways
Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
